Publications by authors named "Olena Barbash"

Claim this Profile
A
Acute resistance to BET inhibitors remodels compensatory transcriptional programs via p300 coactivation.
Viral Shah, George Giotopoulos, Hikari Osaki, Markus Meyerhöfer, Eshwar Meduri, Olena Barbash

Blood· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential Synergistic Effect between Niraparib and Statins in Ovarian Cancer Clinical Trials.
Hailei Zhang, Anna Rutkowska, Antonio González-Martín, Mansoor R Mirza, Bradley J Monk, Olena Barbash

Cancer Res Commun· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I/II study of the clinical activity and safety of GSK3326595 in patients with myeloid neoplasms.
Justin Watts, Mark D Minden, Kimo Bachiashvili, Andrew M Brunner, Sameem Abedin, Olena Barbash

Ther Adv Hematol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor-positive/HER2-negative Advanced or Metastatic Breast Cancer.
David W Cescon, John Hilton, Serafin Morales Murilo, Rachel M Layman, Timothy Pluard, Olena Barbash

Clin Cancer Res· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies.
Mark A Dawson, Gautam Borthakur, Brian J P Huntly, Anastasios Karadimitris, Adrian Alegre, Olena Barbash

Clin Cancer Res· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma.
Tatiana Erazo, Chiara M Evans, Daniel Zakheim, Eren L Chu, Alice Yunsi Refermat, Olena Barbash

Nat Commun· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell-Mediated Antitumor Immune Responses.
Andrew Fedoriw, Leilei Shi, Shane O'Brien, Kimberly N Smitheman, Yunfei Wang, Olena Barbash

Cancer Immunol Res· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Chemical Acetylation-Based Mass Spectrometry Platform for Histone Methylation Profiling.
Francesca Zappacosta, Craig D Wagner, Anthony Della Pietra, Sarah V Gerhart, Kathryn Keenan, Olena Barbash

Mol Cell Proteomics· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Homologous Recombination Deficiency: Concepts, Definitions, and Assays.
Mark D Stewart, Diana Merino Vega, Rebecca C Arend, Jonathan F Baden, Olena Barbash

Oncologist· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Limited antitumor activity of combined BET and MEK inhibition in neuroblastoma.
Jason R Healy, Lori S Hart, Alexander L Shazad, Maria E Gagliardi, Matthew Tsang, Olena Barbash

Pediatr Blood Cancer· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors.
Sarina A Piha-Paul, Christine L Hann, Christopher A French, Sophie Cousin, Irene Braña, Olena Barbash

JNCI Cancer Spectr· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation.
Jia Yi Fong, Luca Pignata, Pierre-Alexis Goy, Kimihito Cojin Kawabata, Stanley Chun-Wei Lee, Olena Barbash

Cancer Cell· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss.
Andrew Fedoriw, Satyajit R Rajapurkar, Shane O'Brien, Sarah V Gerhart, Lorna H Mitchell, Olena Barbash

Cancer Cell· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia.
Charles C Bell, Katie A Fennell, Yih-Chih Chan, Florian Rambow, Miriam M Yeung, Olena Barbash

Nat Commun· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer.
Helai P Mohammad, Olena Barbash, Caretha L Creasy

Nat Med· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
"
"Z4" Complex Member Fusions in NUT Carcinoma: Implications for a Novel Oncogenic Mechanism.
Hitoshi Shiota, Janine E Elya, Artyom A Alekseyenko, Pauline M Chou, Shelby A Gorman, Olena Barbash

Mol Cancer Res· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing.
Sarah V Gerhart, Wendy A Kellner, Christine Thompson, Melissa B Pappalardi, Xi-Ping Zhang, Olena Barbash

Sci Rep· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting Histone Methylation in Cancer.
Michael T McCabe, Helai P Mohammad, Olena Barbash, Ryan G Kruger

Cancer J· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MEK inhibitors overcome resistance to BET inhibition across a number of solid and hematologic cancers.
Anastasia Wyce, Jeanne J Matteo, Shawn W Foley, Daniel J Felitsky, Satyajit R Rajapurkar, Olena Barbash

Oncogenesis· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PRMT5 Is a Critical Regulator of Breast Cancer Stem Cell Function via Histone Methylation and FOXP1 Expression.
Kelly Chiang, Agnieszka E Zielinska, Abeer M Shaaban, Maria Pilar Sanchez-Bailon, James Jarrold, Olena Barbash

Cell Rep· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models.
Elayne Chan-Penebre, Kristy G Kuplast, Christina R Majer, P Ann Boriack-Sjodin, Tim J Wigle, Olena Barbash

Nat Chem Biol· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer.
Pawel K Mazur, Nicolas Reynoird, Purvesh Khatri, Pascal W T C Jansen, Alex W Wilkinson, Olena Barbash

Nature· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762.
Aristeidis Chaidos, Valentina Caputo, Katerina Gouvedenou, Binbin Liu, Ilaria Marigo, Olena Barbash

Blood· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer.
Anastasia Wyce, Yan Degenhardt, Yuchen Bai, BaoChau Le, Susan Korenchuk, Olena Barbash

Oncotarget· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The FBXO4 tumor suppressor functions as a barrier to BRAFV600E-dependent metastatic melanoma.
Eric K Lee, Zhaorui Lian, Kurt D'Andrea, Richard Letrero, WeiQi Sheng, Olena Barbash

Mol Cell Biol· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis